08:03 AM EST, 11/11/2024 (MT Newswires) -- Zai Lab ( ZLAB ) and argenx (ARGX) said Monday that China's National Medical Products Administration has approved Vyvgart Hytrulo to treat chronic inflammatory demyelinating polyneuropathy, a neuromuscular disorder, in adult patients.
The companies said the approval is supported by trial data from a subgroup analysis of Chinese participants which showed a 69% reduction in the risk of relapse with Vyvgart Hytrulo, compared to placebo.